

An oval-shaped stamp from the OPIE (Office of the Patent and Trademark Office) featuring the acronym "OPIE" at the top and "TRADEMARK OFFICE" at the bottom. The center contains the date "APR 21 2004".

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO. 1331-334	SERIAL NO. 09/763,955	
APPLICANT VON BORSTEL			
(Use several sheets if necessary)		FILING DATE February 28, 2001	TC/A.U. 1623

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

PK	Page, T., et al; "A Syndrome of Megaloblastic Anemia, Immunodeficiency, and Excessive Nucleotide Degradation"; <i>Purine and Pyrimidine Metabolism in Man VII, Part B</i> ; pp. 345-348 (1991).
↓	Page, T., et al; "A Syndrome of Seizures and Pervasive Development Disorder Associated with Excessive Cellular Nucleotidase Activity"; <i>Purine and Pyrimidine Metabolism in Man IX</i> ; pp. 789-792 (1998).
↓	Ferrante, R.J., et al; "Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease"; <i>The Journal of Neuroscience</i> ; 20(12), pp 4389-4397, June 15, 2000.
↓	Du, Y., et al; "Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease"; <i>PNAS</i> , Vol. 98, No. 25; pp. 14469-14674 (December 4, 2001).
PK	Ravina, B.M., et al; "Neuroprotective Agents for Clinical Trials in Parkinson's Disease"; <i>American Academy of Neurology</i> ; 60, pp. 1234-1240 (2003).

*Examiner

Date Considered

7-27-06

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.